Study of QL0911 for children with immune thrombocytopenia (ITP)
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests if a new medicine called QL0911 can help children with chronic ITP who haven't improved with standard treatments. It aims to raise platelet counts and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 and 17 years old.
- You have had ITP (low platelets) for at least 12 months.
- You have tried at least one first-line ITP treatment and it didn't work or your ITP came back.
- Your platelet count was less than 30,000 within the last 48 hours before starting the study.
- You must be generally active and able to do everyday activities (ECOG score 0, 1, or 2).
- If you could have children, you must agree to use effective birth control during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new tablet called TQB3473 for adults with persistent or long-lasting primary ITP. It is for people whose platelet counts stay low despite past treatments, and aims to see if the drug can safely raise platelet levels and reduce bleeding risk.
This trial tests an investigational tablet called TQB3473 against placebo for adults with primary immune thrombocytopenia (ITP) that has lasted at least a year and hasn't responded well to standard treatments. The goal is to see if the drug can safely increase platelet counts and reduce bleeding risk.
This trial tests whether adding ianalumab to eltrombopag helps children with immune thrombocytopenia (ITP) who didn't get better with steroids. It aims to find a new option for kids whose platelet counts are low despite treatment.
This trial tests a new drug called QL0911 to help raise platelet counts in people with cancer whose chemo has caused low platelets. The goal is to see if it can prevent delays in treatment.
This trial tests a new treatment called universal allogeneic CAR T-cell therapy (QT-019C) for adults with severe, hard-to-treat immune thrombocytopenia (ITP). It aims to see if targeting CD19 and BCMA on immune cells can safely improve platelet counts.
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
Hear when a new Thrombocytopenia, Immune trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.